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BASICS OF COMPOUNDING

Vehicles for Compounded Oral
Liquid Medications: A Review
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Lipika Chablani, PhD
Fang Zhao, PhD

Abstract
Compounded oral liquid medications play an important role In addressing the unmet needs
of special patient popuiations, including pediatric, geriatric, and tube-fed patients. The use
of manufactured vehicles can streamline the compounding activities for pharmacists. In
recent years, there is an increase in the availability of manufactured vehicies with various
promotionai features. This articie uses the general formulation principies as a guide to
compare and contrast the manufactured vehicles regarding their physicochemical properties,
presence of preservatives and dyes, organoleptic properties, and ease of use. A summary
tabie is provided as a reference tool to assist pharmacists in selecting the optimal vehicles for
their patient care.

International Journal of Pharmaceutical Compounding

480

22 No. 6 I November December 2018

The authors’ affiliations
are: Kara Cutaia, Resident
Pharmacist, Unity Hospital,
Rochester Regional Health,
Rochester, New York; Lipika
Chablani, Associate Professor,
and Fang Zhao, Professor,
Department ofPharmaceutical
Sciences, St. John Fisher Col
lege Wegmans School ofPhar
macy, Rochester, New York.

unvw.lJPC.com

Unmedicated oral vehicles are used
to prepare oral liquid medications.
Compounding of oral liquid formulations
expands treatment options for patients who
have difficulty swallowing tablets or cap
sules, as extemporaneous preparation can
provide dosage forms that are not commer
cially available. Specific populations who
may benefit from the compounding of these
dosage forms include pediatric patients,
geriatric patients, and patients with enteral
feeding tubes. Multiple oral vehicles are
available, and these products differ in their
physicochemical and organoleptic proper
ties. These vehicles can be used to prepare
a variety of oral liquid dosage forms includ
ing solutions, suspensions, and emulsions.
This article provides a review of commer
cially available oral vehicles as well as a
discussion of vehicle properties to consider
when selecting a vehicle for a specific drug,
route, and patient. This information may
serve as a reference for compounding phar
macists as well as for persons involved in
formulating oral-liquid dosage forms for
commercial applications.

Discussion
We have reviewed 26 oral liquid
vehicles, considering various aspects
such as:
• Appearance
• Osmolality
• pH
• Presence of preservatives and dyes
• Viscosity
• Suspending agent used
• Taste

This information is summarized in Table
1 as a reference tool for compounding phar
macists. Additionally, we have examined
published literature and reference books to
provide context for this data.

Physicochemical
Properties
Oral dosage forms should be palatable and
well tolerated, provide accurate and consis-
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tent dosing, and maintain physical integrity
throughout their shelf life.^ Physiochemical
properties to consider when preparing oral
liquid formulations include viscosity, sus
pending agent, pH, and osmolality.
VISCOSITY AND SUSPENDING
AGENT

Oral liquid dosage forms include solu
tions, suspensions, and emulsions. In solu
tions, ingredients are solubilized in the
solvent. Types of oral solutions include syr
ups, elixirs, spirits, and tinctures. Multiple
syrups are commercially available as oral
liquid vehicles. These do not contain sus
pending agents, and viscosity is essential
primarily for pharmaceutical elegance and
ease ofuse.^
Suspensions are dispersed systems
which have physical-stability challenges.
An ideal suspension settles slowly and
readily re-disperses upon agitation.®
During storage, suspensions may undergo
sedimentation and aggregation (including
cake formation) leading to physical insta
bility and variability in dosing. Inconsistent
dosing can have severe consequences
for patients including drug toxicity and,
conversely, undertreatment. Increased
viscosity of suspensions can slow the rate
of particle setting. However, if viscosity
is too high, the particles may be less read
ily re-dispersed upon agitation, and the
product may be difficult to pour and mea
sure.^'® Suspensions are formulated with
suspending agents that maintain the physi
cal stability of the dispersion throughout
the shelf life. Most of these suspending
agents are pseudoplastic or shear-thinning
systems, which leads to lowering of viscos
ity with respect to increased shear stress
(i.e., shaking of the bottle or trituration of
the ingredients to compound the suspen
sion). Along with the pseudoplastic rheol
ogy, these systems are also thixotropic, a
property which allows the system to regain
its viscosity once the shear stress has been
removed from the system. The thixotropic
behavior of such commercial oral vehicles
enhances the stability and shelf life of the
compounded oral dispersions.

Like suspensions, emulsions are dis
persed systems. Specifically, emulsions
are dispersions of small globules of a sub
stance in a vehicle in which it is immiscible.
Because emulsions contain at least two
phases, often an aqueous and an oleaginous
phase, they provide a liquid dosage form
more suitable for drugs that are unstable
in aqueous formulations. Physical stability
challenges for emulsions include cream
ing (weak associations between droplets of
the internal phase) and cracking (irrevers
ible coalescence of droplets of the internal
phase). Viscosity regulators and thickening
agents may be added to emulsions to slow
the rate of particle settling and improve the
stability of the dispersion.® An example of
an oral liquid vehicle available as an emul
sification system is Fagron's Unispend
Anhydrous. This vehicle, available both
sweetened and unsweetened, is formulated
with triglycerides and provides an anhy
drous system which is favorable for water
unstable additives.^
As evident from Table 1, common sus
pending agents/viscosity enhancers include
sodium carboxymethylcellulose, xanthan
gum, and carrageenan. Each of these agents
poses their own incompatibility issues that
a compounding pharmacist must consider
while using the commercial oral vehicles
that contain them. A detailed description
of incompatibility concerns for each of
these agents is available in the Handbook
ofPharmaceutical Excipients f This study
provides a brief overview of some of these
major incompatibilities with respect to
each of these agents. Sodium carboxymeth
ylcellulose solutions are most stable at pH 5
to 10, however, those solutions can tolerate
a broader range of pH 2 to 10 for final prepa
rations. These solutions are also incompat
ible with quaternary nitrogen-containing
compounds, iron salts, and metals such as
aluminum, mercury, and zinc. Similarly,
due to the anionic chemical structure of
xanthan gum, it is incompatible with large
cationic drugs, surfactants, polymers, and
preservatives. Xanthan gum is also incom
patible with oxidizing agents, some tablet
film-coatings, dried aluminum hydroxide
gel, and some active ingredients such as
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1
amitriptyline, tamoxifen, and verapamil.
Lastly, carrageenan-containing solutions
remain stable at pH 9 and can lead to its
depolymerization if the pH of the solution
is rendered acidic. Also, carrageenan may
interact with cationic active pharmaceuti
cal ingredients and is generally limited in
its use in such cases.
A recent study by Visser et al® compares
the rheological and sedimentation behavior
of some of the commercially available oral
vehicles. The study describes the prepara
tion of an oral suspension of paracetamol
to evaluate the efficacy of the following
oral vehicles:
• Base for Suspension
• Ora-Blend
• Ora-Blend SF
• Simple Syrup
• Suspendit
• Syr-Spend SF PFI4

1
1
i

i
I
■i
1
;!
1

The study concludes that SyrSpend SF
PH4 and Suspendit resulted in the bestcompounded preparations due to their
pronounced pseudoplastic rheological
profile. Both the vehicles provided adequate
sedimentation rates, even pourability, and
good resuspendability. These results are
promising. However, the study can further
be expanded to include other commercially
available vehicles.
pH

Because many drugs are weak electro
lytes (weak acids or weak bases), the pH
of the formulation affects drug ionization,
solubility, and physicochemical stability.
Vehicles and formulations may be prepared
with buffers to prevent sudden changes in
pH.’' When selecting a vehicle for the oral
liquid formulation, consideration should be
given to any data regarding the effect of pH
on the solubility and stability of the drug
being prepared in the formulation. Most
of the oral liquid vehicles described in this
review have an acidic pH. For drugs that are
unstable in acidic pH, cdkaline vehicles are
available. An example of such a product is
Fagron's SyrSpend SF Alka, which has a pH
of >7.

OSMOLALITY
Oral vehicles with high osmolality have
the potential to cause gastrointestinal
(GI) upset and diarrhea.®*^® Some special
patient populations are particularly prone
to osmotic diarrhea. They include pediatric
patients, geriatric patients, and patients
with GI comorbidities such as irritable
bowel syndrome. For instance, hyper
tonic solutions of >400 mOsm/kg were
reported to injure GI tracts of neonates.®
Unfortunately, the osmolality data are not
available for all vehicles from the manu
facturers, and estimation is difficult for
vehicles with proprietary formulas. The fol
lowing discussion is based on the vehicles
with reported values (Table 1) and general
scientific knowledge of oral liquid formula
tions and excipients.’^^
The osmolality of the normal GI fluids is
between 100 mOsm/kg to 400 mOsm/kg.’®
Several sugar-based syrup vehicles contain
high concentrations of sucrose which result
in extremely high osmolality. For example,
the osmolality is 4109 mOsm/kg for OraSweet (Perrigo) and 2381 mOsm/kg for Oral
Syrup (Medisca). The same issue exists
for some sugar-free vehicles, depending on
the sweeteners used. Generally, the natural
polyol sweeteners (e.g., sorbitol) have much
lower sweetness than the artificial sweeten
ers (e.g., sucralose) si®!"* and thus require
much higher concentrations in the formula
tion. For example, sorbitol is used in a num
ber of commercial vehicles, and it is only
about 50% to 70% as sweet as sucrose.^®
Hence, a vehicle sweetened mainly by sor
bitol still requires a high concentration of
sorbitol, which again leads to hyperosmolal
ity. Furthermore, sorbitol is only partially
absorbed in the GI tract. The non-absorbed
sorbitol is fermented by the colonic flora
with gaseous byproducts, which exacerbate
the GI disturbances.’® As a safe practice,
the compounding pharmacist should make
sure that the sorbitol consumption from
the prescribed dosage is below 20 g/day
for adults.® ’® On the other hand, the nonsweetened suspension vehicles tend to have
low osmolality, which are suitable choices
for patients who cannot tolerate hypertonic
liquids. Two good vehicle examples are Ora-

Plus from Perrigo and Oral Suspend from
Medisca at 157 mOsm/kg and 48 mOsm/kg,
respectively. Finally, one notable product
worth highlighting is SyrSpend SF from
Fagron. It is the only all-in-one vehicle
(sweetened, flavored, structured) with a low
osmolality of <50 mOsm/kg. In addition,
there are two similar SyrSpend SF powder
products which are preservative-free but
require reconstitution before use.
The concern of GI distress is heightened
when the oral liquids are administered via
enteral feeding tubes.® ’® Depending on the
tubing types, the liquid medications are
delivered directly to various GI regions
without dilution. As expected, the adverse
effects are most pronounced when the
liquids are administered too rapidly into
the stomach or delivered directly to the
intestine. Since palatability is not a require
ment for medications administered via
enteral feeding tube, it is recommended to
choose non-sweetened, non-flavored, and
low-osmolality vehicles. If the viscosity of
these vehicles presents a challenge for some
narrow tubes, they should be diluted with
purified water rather than another vehicle
with high osmolality.

Preservatives and Dyes
Preservatives are often included in the
formulations of oral liquid vehicles to pro
vide microbial stability. Aqueous formula
tions are prone to microbial growth, and
preservatives protect against bacterial,
yeast, and mold infection. In addition to
protecting the end user from pathogens,
preservatives also provide a multiple year
shelf life for products. Parabens are the
most commonly-used class of preservatives
which offer protection against a wide range
of pathogens, even at low concentrations.
Both methylparabens and propylparabens
have low aqueous solubilities (1 g/400 mL
of water and 1 g/ 2,500 mL of water, respec
tively) and are often solubilized with the
aid of small amounts of a co-solvent such as
alcohol or propylene glycol. Methylparaben
is often used as a preferred preservative,
as it can effectively preserve oral vehicles
for a broader pH range of 4 to 8. Often,
methylparaben is paired with propylpara-
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ben to achieve a synergistic effect and allow
the use of low concentrations. Due in part to
consumer perceptions, many preservative-free
or paraben-free products are currently being
marketed. However, available evidence does not
support a need to avoid parabens, and the safety
and efficacy of parabens have repeatedly been
reported. Many prestigious health organiza
tions worldwide, including the U.S. Food and
Drug Administration, continue to support the
use of parabens.^® As evident from Table 1, other
commonly used preservatives for oral vehicles
include sodium benzoate and potassium sorbate. Sodium benzoate can be effectively used
to preserve oral liquids with a pH <5. Several of
the commercial oral vehicles, including syrups,
satisfy this qualification and are effectively
preserved with this water-soluble preserva
tive. Sodium benzoate’s pH-dependent efficacy
should be considered with respect to the pH of
the resulting compounded preparations using
such oral vehicles. Similarly, potassium sorbate
can be effectively used as a preservative for oral
vehicles and formulations with a pH <6. Unlike
the parabens, potassium sorbate is very soluble
in aqueous systems (1 g/ 4.5 mL of water) and
does not require any co-solvents. Additionally,
Bruns et al also compares the stability of these
common preservatives and concludes that
potassium sorbate is the safest alternative for
pediatric patients with respect to its efficacy
for compounded oral preparations with a pH of
3.5 to 5.5.1’'
Dyes provide pharmaceutical elegance to liq
uid dosage forms. Multiple oral liquid vehicles
contain dyes, often Red #3 and FD&C #40. For
patients who are allergic or sensitive to dyes,
many dye-free vehicles also are available.
Because neonates have relatively limited meta
bolic activity, both preservative- and dye-free
oral liquid vehicles are preferred for this popu
lation. Compounded oral preprirations for this
population are generally prepared in limited
quantities, stored in refrigerators, and consumed
immediately or within short durations from
preparation to avoid the use of preservatives.

Organoleptic Properties
Organoleptic properties pertinent to oral
liquid vehicles include taste, sweetness, and
appearance. Patient adherence to therapy may
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Practitioners should consider
the effect of sweeteners, poten
tially avoiding those that cause
diarrhea in certain patients,
while recognizing that laxa
tive effects may actually be
beneficial for patients who
are chronically constipated.
The physical appearance of
commercially available oral
vehicles varies, ranging from
clear to hazy and colorless to
tinted (tjT)ically pink or red
if colored). Multiple com
mercially available oral vehicles are also capable of
taste-masking, which further enhances the palatability
of compounded formulations, particularly when addi
tives have an unpleasant taste.
In patients who are receiving medications through
an enteral feeding tube, organoleptic properties are
less important as the patient wiU not experience taste
and sweetness
due to the route
of drug delivery.
However, physico
chemical proper
ties remain crucial
as feeding tubes
SOFTWARE THAT WORKS FOR YOU
present unique
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be enhanced when the dosage
form is palatable and pharma
ceutically elegant. Some oral
vehicles are flavored, while oth
ers are unflavored, allowing the
compounding pharmacist to
add flavors that match patient
preference. Syrups have a high
degree of sweetness, which
may be appealing to particu
lar patient populations such
as pediatric patients. Some
vehicles contain sugar-free
sweeteners (including sugar
alcohols) with the advantage
of the lower glycemic load for
diabetic patients. As discussed
previously under the topic of
osmolality, sugar alcohols such
as sorbitol can cause osmotic
diarrhea, as can sugars.®

Practitioners should consider the effect

ofsweeteners, potentially avoiding those
that cause diarrhea in certain patients,
while recognizing that laxative effects

may actually be beneficial for patients
who are chronically constipated.

RS SOFTWARE

POWERFUL USER FRIENOLY

Ease of Use
OUR SYSTEMS THAT WORK FOR YOU
•
•
•
•

Script Assist
Compound Assist
Prescription Assist
HIPAABank

Norman, OK

|

(405)321-5356

|

support@rssoftware.net

International Journal of Pharmaceutical Compounding

488

yqi

22 No. 6 j November ; December | 2018

For ease of use,
oral vehicles ide
ally permit pour
ing, measuring,
withdrawal into an
oral syringe, and
instillation through
an enteral feed
ing tube. Viscosity

should be maintained within a range high
enough to maintain physical stability but
low enough to permit these procedures. To
further facilitate ease of use, the product
should re-disperse readily upon simple
agitation.® Prolonged or vigorous agitation
may be time consuming or complicated for
providers and patients alike. Additionally,
patients, pharmacists, and caregivers may
have different interpretations of the direc
tions “Shake well before using.”® Dosage
forms prepared with oral liquid vehicles
should be able to provide uniform contents
after simple manual agitation.
Additionally, most of these oral vehicles
are avculable in conveniently packaged
one-pint contciiners (473 mL), with a
24- to 36-month shelf life. This allows
the pharmacist to easily stock and store
these buffered, sweetened, flavored, and
preserved oral vehicles in their inventory.
Further, current published literature pro
vides a plethora of information regarding
the formulation and stability of several
active pharmaceutical ingredients in these
commercial vehicles. This strengthens
the database for utilizing these vehicles to
provide improved patient care. Due to the
stability and versatile applications of these
vehicles for compounded oral-liquid dos
age forms, several pharmacies have phased
out from preparing their in-house United
States Pharmacopeia-compliant oral vehi
cles. The resulting increase in demand and
competition by several manufacturers for
these vehicles thereby feeds the cost-tobenefit ratio of purchasing these vehicles.
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Cost Comparison
Standardized, current pricing informa
tion was not readily available for all the
products. However, the average wholesale
price (AWP) reported in Red Book ranged
from approximately $16 to $63 (USD) per
473 mL.^® The actual cost of obtaining the
vehicles can vary significantly from the
AWP, depending on multiple factors such
as bulk purchasing discounts and contract
pricing between the manufacturer and
buyer. For some of these products, mul
tiple package sizes are available, which
could impact pricing.

Conclusion
In conclusion, multiple un-medicated oral
vehicles are available for use in preparing oral
formulations. By comparing physicochemical
and organoleptic properties, the compound
ing pharmacist can select the oral vehicle best
suited for the drug, route, and patient.
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